论文部分内容阅读
目的:观察厄贝沙坦与苯磺酸左旋氨氯地平治疗原发性高血压的疗效和安全性。方法:将200例原发性高血压病患者随机分为治疗组和对照组,各100例。2组患者分别给予厄贝沙坦150mg·d-(1降压效果不理想者可增至300mg·d-1)与苯磺酸左旋氨氯地平2.5mg·d-(1降压效果不理想者可增至5mg·d-1),均治疗8周。观察治疗前、后2组血压变化及不良反应发生情况。结果:治疗后2组收缩压和舒张压均明显下降(P<0.05),对照组收缩压下降幅度显著>治疗组(P<0.05);治疗组总有效率为87.0%,对照组总有效率为89.0%,2组比较无显著性差异(P>0.05);2组不良反应发生情况比较无统计学意义(P>0.05)。结论:厄贝沙坦与苯磺酸左旋氨氯地平均具有良好的降压作用和较高的安全性。
Objective: To observe the efficacy and safety of irbesartan and levamlodipine besylate in the treatment of essential hypertension. Methods: 200 cases of essential hypertension were randomly divided into treatment group and control group, each 100 cases. Irbesartan 150mg · d- (1 can be increased to 300mg · d-1) and levamlodipine besylate 2.5mg · d- (1) in 2 groups were not satisfactory Who can be increased to 5mg · d-1), were treated for 8 weeks. Before and after treatment, changes of blood pressure and adverse reactions were observed. Results: After treatment, the systolic and diastolic blood pressures were significantly decreased in both groups (P <0.05), while the systolic blood pressure in the control group decreased significantly (P <0.05). The total effective rate was 87.0% in the treatment group. The total effective rate (89.0%). There was no significant difference between the two groups (P> 0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: Irbesartan and levamisole besylate have good antihypertensive effect and high safety.